MedTrace Logo

Treatment of Wounds Using Oasis® ECM

NCT03632031 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2026-02-18

No results posted yet for this study

Summary

The purpose of this clinical study is to gather post-market clinical evidence on the use of Oasis ECM as a treatment for donor site wounds in the community setting in the United Kingdom.

Conditions

  • Non-healing Wound

Interventions

DEVICE

Oasis Extracellular Matrix

Patients will receive OASIS Extracellular Matrix according to the Instruction for Use

OTHER

Standard Care (in control arm)

Donor site will be treated with standard care.

Sponsors & Collaborators

  • Cook Biotech Incorporated

    lead INDUSTRY

Principal Investigators

  • Leanne Atkin, PhD · Mid Yorkshire Teaching NHS Trust

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-01
Primary Completion
2025-03-01
Completion
2025-09-26
FDA Device
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03632031 on ClinicalTrials.gov